NCT04602273View on ClinicalTrials.gov

Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)

UnknownOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

December 12, 2016

Primary Completion Date

November 1, 2020

Study Completion Date

June 30, 2021

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Azacitidine Injection [Vidaza]

Trial Locations (1)

07198

RECRUITING

Son Llàtzer, Palma

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Hospital Son Llatzer

OTHER

collaborator

Germans Trias i Pujol Hospital

OTHER

collaborator

Celgene Corporation

INDUSTRY

lead

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias

OTHER